Pure Global AI
NCT06232265Recruiting

An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore

An Observational Study on Predicting the Efficacy of Immunotherapy for Non-small-cell Lung Cancer Based on LIRAscore
Nanfang Hospital, Southern Medical UniversityClinicalTrials.gov
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Nanfang Hospital, Southern Medical University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Sep 22, 2023
End date
Aug 01, 2026
Enrollment
108 participants
Primary outcome

Objective Response Rate (ORR)

Summary

This is a multi-center, observational clinical study to explore the role of LIRAscore in
 predicting immunotherapy monotherapy and combination with chemotherapy efficacy and prognosis
 in locally advanced or metastatic non-small-cell lung cancer. The study plans to enroll 108
 patients. The primary endpoint of this study was ORR, and secondary endpoints were PFS, OS,
 DoR, DCR, and safety.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06232265
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06232265 through Pure Global AI's free database. This phase not specified trial is sponsored by Nanfang Hospital, Southern Medical University and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 108 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.